Retirement Systems of Alabama lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 14.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,211 shares of the medical instruments supplier’s stock after buying an additional 8,327 shares during the period. Retirement Systems of Alabama’s holdings in Becton, Dickinson and Company were worth $11,852,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of BDX. Maryland Capital Advisors Inc. boosted its holdings in shares of Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 139 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Main Street Group LTD acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $29,000. Bell Investment Advisors Inc bought a new position in Becton, Dickinson and Company in the second quarter valued at about $29,000. Finally, Kelleher Financial Advisors bought a new position in Becton, Dickinson and Company in the second quarter valued at about $30,000. 86.97% of the stock is currently owned by institutional investors.
Becton, Dickinson and Company Stock Performance
NYSE BDX opened at $217.95 on Monday. The company has a market capitalization of $60.05 billion, a price-to-earnings ratio of 52.64, a PEG ratio of 3.65 and a beta of 0.22. The company has a quick ratio of 0.54, a current ratio of 0.87 and a debt-to-equity ratio of 0.54. Becton, Dickinson and Company has a twelve month low of $140.11 and a twelve month high of $219.78. The stock has a fifty day simple moving average of $190.90 and a 200 day simple moving average of $170.56.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.96 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 13.21 EPS for the current year.
Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback program on Thursday, November 5th that permits the company to buy back 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 3.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its stock is undervalued.
Becton, Dickinson and Company Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a dividend yield of 1.9%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio is 101.45%.
Insider Transactions at Becton, Dickinson and Company
In other news, CEO Thomas Polen, Jr. sold 2,993 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total transaction of $628,530.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,310 shares of company stock valued at $688,650 over the last 90 days. 0.40% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on BDX. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research note on Friday, August 7th. JPMorgan Chase & Co. upped their price objective on Becton, Dickinson and Company from $170.00 to $202.00 and gave the company a “neutral” rating in a research note on Friday, November 6th. Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, November 6th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $197.47.
Read Our Latest Report on Becton, Dickinson and Company
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Further Reading
- Five stocks we like better than Becton, Dickinson and Company
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
